Status:
WITHDRAWN
Calcium, Phosphate, Renal Impairment and Coronary Artery Disease in the Cardio-renal Syndrome, The CAPRICORN-CRS Study
Lead Sponsor:
Massachusetts General Hospital
Conditions:
Heart Failure
Eligibility:
All Genders
18+ years
Brief Summary
Heart failure (HF) is a major public health problem, which affects about 5 million Americans.HF is when the heart muscle does not pump as much blood as the body needs. As a result of this,the body has...
Detailed Description
The interaction between cardiac and renal (dys)function has been a highly relevant, yet poorly understood phenomena to both clinicians and scientists. More than 50% of the heart failure patients suffe...
Eligibility Criteria
Inclusion
- Men and women of 18 years old or older
- history and clinical findings of heart failure for at least three months before screening
- Patients have to be in New York Heart Association (NYHA) class II, III, or IV and clinically stable
- Left ventricular ejection fraction \<50%
- GFR ≤ 40 ml/min/1.73m² as calculated the abbreviated MDRD formula
Exclusion
- pregnancy as determined by urine test for reproductive-aged females
- current or past renal replacement therapy
- current treatment for hyperphosphatemia
- a history of renal transplantation or CABG
- Symptoms consistent with Canadian Cardiovascular Society \> class 1 angina
- Inability to comprehend or unwillingness to sign informed consent
- chronic atrial fibrillation
Key Trial Info
Start Date :
March 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00853541
Start Date
March 1 2009
End Date
October 1 2011
Last Update
September 24 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114